Preoperative use of radiation boost to enhance effectiveness

Recruiting

99 years or below

All

Phase 1

32 participants needed

1 Location

Brief description of study

Our study is a Phase 1Ib/2 clinical trial to evaluate the safety and feasibility of the combination of radiotherapy (RT) in a single fraction of 7 Gy with pembrolizumab in patients with operable breast cancer. We will employ a Simon Two Stage design to evaluate the safety, feasibility, and efficacy of combination radiation boost and a single pembrolizumab infusion prior to definitive surgery.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: breast cancer
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 833464

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Preoperative use of radiation boost to enhance effectiveness of immune checkpoint blockade therapy in operable breast cancer

Brief description of study

Eligibility of study

Find a site

Interested in the study